Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.

Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC.

Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.

PMID:
29259013
2.

Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy.

McDaniel AS, Hovelson DH, Cani AK, Liu CJ, Zhai Y, Zhang Y, Weizer AZ, Mehra R, Feng FY, Alva AS, Morgan TM, Montgomery JS, Siddiqui J, Sadis S, Bandla S, Williams PD, Cho KR, Rhodes DR, Tomlins SA.

Cancer Res. 2015 Dec 15;75(24):5219-27. doi: 10.1158/0008-5472.CAN-15-1004.

3.

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng FY, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA.

Neoplasia. 2015 Apr;17(4):385-99. doi: 10.1016/j.neo.2015.03.004.

4.

Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA.

Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.

5.

Identification of targetable FGFR gene fusions in diverse cancers.

Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM.

Cancer Discov. 2013 Jun;3(6):636-47. doi: 10.1158/2159-8290.CD-13-0050. Epub 2013 Apr 4.

6.

The mutational landscape of lethal castration-resistant prostate cancer.

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA.

Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.

7.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

8.

Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M.

Genes Dev. 2010 Oct 1;24(19):2219-27. doi: 10.1101/gad.1944810.

9.

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10284-9. doi: 10.1073/pnas.0900351106. Epub 2009 Jun 1.

10.

Exploring clinical associations using '-omics' based enrichment analyses.

Hanauer DA, Rhodes DR, Chinnaiyan AM.

PLoS One. 2009;4(4):e5203. doi: 10.1371/journal.pone.0005203. Epub 2009 Apr 13.

11.

Coactivator function defines the active estrogen receptor alpha cistrome.

Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M.

Mol Cell Biol. 2009 Jun;29(12):3413-23. doi: 10.1128/MCB.00020-09. Epub 2009 Apr 13.

12.

Identifying significant associations using free text problem summary lists in a clinical data repository.

Hanauer DA, Rhodes DR, Chinnaiyan AM.

AMIA Annu Symp Proc. 2007 Oct 11:968.

PMID:
18694068
13.

The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM.

Cancer Cell. 2008 Jun;13(6):519-28. doi: 10.1016/j.ccr.2008.04.016.

14.

A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.

Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM.

Cancer Res. 2007 Nov 15;67(22):10657-63.

15.

Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.

Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM.

Neoplasia. 2007 May;9(5):443-54.

16.

Integrating biomedical knowledge to model pathways of prostate cancer progression.

Morris DS, Tomlins SA, Rhodes DR, Mehra R, Shah RB, Chinnaiyan AM.

Cell Cycle. 2007 May 15;6(10):1177-87. Epub 2007 May 5. Review.

PMID:
17495538
17.

Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM.

Neoplasia. 2007 Feb;9(2):166-80.

18.

Bioinformatics approaches in the study of cancer.

Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM.

Curr Mol Med. 2007 Feb;7(1):133-41. Review.

PMID:
17311538
19.

Integrative molecular concept modeling of prostate cancer progression.

Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.

Nat Genet. 2007 Jan;39(1):41-51. Epub 2006 Dec 17.

PMID:
17173048
20.

Whole transcriptome amplification for gene expression profiling and development of molecular archives.

Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening E, Makarov V, Chinnaiyan AM.

Neoplasia. 2006 Feb;8(2):153-62.

21.

Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.

Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93.

22.

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM.

Cancer Res. 2006 Apr 1;66(7):3396-400.

23.

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM.

Cancer Cell. 2005 Nov;8(5):393-406.

24.

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.

Science. 2005 Oct 28;310(5748):644-8.

25.

Probabilistic model of the human protein-protein interaction network.

Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, Pandey A, Chinnaiyan AM.

Nat Biotechnol. 2005 Aug;23(8):951-9.

PMID:
16082366
26.

Integrative analysis of the cancer transcriptome.

Rhodes DR, Chinnaiyan AM.

Nat Genet. 2005 Jun;37 Suppl:S31-7. Review.

PMID:
15920528
27.

Mining for regulatory programs in the cancer transcriptome.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.

Nat Genet. 2005 Jun;37(6):579-83.

PMID:
15920519
28.
29.

Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14. Epub 2004 Jun 7.

30.

Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.

J Natl Cancer Inst. 2004 Jun 2;96(11):834-43. Erratum in: J Natl Cancer Inst. 2004 Jul 21;96(14):1112.

PMID:
15173267
31.

Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM.

Cancer Res. 2004 Jun 1;64(11):3814-22.

32.

ONCOMINE: a cancer microarray database and integrated data-mining platform.

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.

Neoplasia. 2004 Jan-Feb;6(1):1-6.

33.

Prostate cancer biomarkers: a current perspective.

Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM.

Expert Rev Mol Diagn. 2003 Jul;3(4):459-70. Review.

PMID:
12877385
34.

Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.

Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA.

J Natl Cancer Inst. 2003 May 7;95(9):661-8.

PMID:
12734317
35.

Dysregulation of the annexin family protein family is associated with prostate cancer progression.

Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA.

Am J Pathol. 2003 Jan;162(1):255-61.

36.

DNA microarrays: implications for clinical medicine.

Rhodes DR, Chinnaiyan AM.

J Invest Surg. 2002 Sep-Oct;15(5):275-9. Review.

PMID:
12396431
37.

Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.

Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM.

Cancer Res. 2002 Aug 1;62(15):4427-33.

38.

CIT: identification of differentially expressed clusters of genes from microarray data.

Rhodes DR, Miller JC, Haab BB, Furge KA.

Bioinformatics. 2002 Jan;18(1):205-6.

PMID:
11836234
39.

Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.

Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9. Epub 2001 Aug 7.

40.

Tolerance of the hypertrophic heart to ischemia. Studies in compensated and failing dog hearts with pressure overload hypertrophy.

Gaasch WH, Zile MR, Hoshino PK, Weinberg EO, Rhodes DR, Apstein CS.

Circulation. 1990 May;81(5):1644-53.

PMID:
2139593
41.

Method for determining H2SO4 in automobile exhaust.

Kipp KL, Rhodes DR.

Environ Health Perspect. 1975 Apr;10:109-12.

42.

On a third kind of characteristic numbers of the spheroidal functions.

Rhodes DR.

Proc Natl Acad Sci U S A. 1970 Sep;67(1):351-5.

Supplemental Content

Loading ...
Support Center